Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a medicine that is used to treat prostate cancer in adults. Pluvicto may be used to treat PSMA-positive prostate cancer that has spread to other ...
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion. Pluvicto is ...
Novartis announced the pivotal phase III PSMAfore study with Pluvicto (INN: lutetium (177Lu) vipivotide tetraxetan), a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its ...
Novartis has high hopes for its radiotherapy Pluvicto. But as the Swiss pharma aims to move the drug into an earlier treatment setting in prostate cancer, it has posted a mixed bag of trial data that ...
Novartis announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC ...
Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto to include hormone-sensitive prostate cancer (HSPC). The new results come from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results